The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

BACKGROUND: PARP1 facilitates the recovery of DNA-damaged cells by recruiting DNA damage response molecules such as γH2AX and BRCA1/2, and plays a role in resistance to antitumor therapies. Therefore, PARP inhibition being evaluated as an anti-cancer therapy. However, there are limited studies regra...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Exp Clin Cancer Res
Egile Nagusiak: Park, Hye Jeong, Bae, Jun Sang, Kim, Kyoung Min, Moon, Young Jae, Park, See-Hyoung, Ha, Sang Hoon, Hussein, Usama Khamis, Zhang, Zhongkai, Park, Ho Sung, Park, Byung-Hyun, Moon, Woo Sung, Kim, Jung Ryul, Jang, Kyu Yun
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2018
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5963190/
https://ncbi.nlm.nih.gov/pubmed/29784019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-018-0772-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak